Equities Analysts Offer Predictions for RIGL FY2026 Earnings

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) – Analysts at HC Wainwright decreased their FY2026 earnings estimates for shares of Rigel Pharmaceuticals in a research note issued on Wednesday, November 5th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of $5.19 for the year, down from their prior forecast of $5.78. HC Wainwright currently has a “Buy” rating and a $57.00 target price on the stock. The consensus estimate for Rigel Pharmaceuticals’ current full-year earnings is $0.22 per share. HC Wainwright also issued estimates for Rigel Pharmaceuticals’ FY2027 earnings at $6.30 EPS and FY2028 earnings at $7.39 EPS.

RIGL has been the subject of several other research reports. Zacks Research upgraded shares of Rigel Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday. Cantor Fitzgerald increased their price target on shares of Rigel Pharmaceuticals from $32.00 to $38.00 and gave the stock a “neutral” rating in a research note on Wednesday. Jefferies Financial Group raised shares of Rigel Pharmaceuticals from a “hold” rating to a “buy” rating and upped their price objective for the stock from $23.00 to $42.00 in a report on Wednesday. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $39.83.

Rigel Pharmaceuticals Stock Down 2.6%

NASDAQ RIGL traded down $0.95 during mid-day trading on Friday, reaching $35.18. 216,449 shares of the company’s stock traded hands, compared to its average volume of 384,687. The company has a fifty day simple moving average of $32.35 and a 200-day simple moving average of $26.16. Rigel Pharmaceuticals has a 1-year low of $14.63 and a 1-year high of $43.72. The company has a market cap of $630.93 million, a price-to-earnings ratio of 6.50 and a beta of 1.22. The company has a current ratio of 2.02, a quick ratio of 1.90 and a debt-to-equity ratio of 0.46.

Rigel Pharmaceuticals (NASDAQ:RIGL) last issued its earnings results on Tuesday, November 4th. The biotechnology company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $0.93 by $0.53. The company had revenue of $69.46 million for the quarter, compared to analyst estimates of $61.88 million. Rigel Pharmaceuticals had a net margin of 36.51% and a return on equity of 438.89%. Rigel Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Trading of Rigel Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Dynamic Technology Lab Private Ltd bought a new stake in shares of Rigel Pharmaceuticals during the first quarter worth $488,000. Strs Ohio bought a new position in shares of Rigel Pharmaceuticals in the 1st quarter valued at about $389,000. Acadian Asset Management LLC grew its position in shares of Rigel Pharmaceuticals by 50.1% during the 1st quarter. Acadian Asset Management LLC now owns 565,045 shares of the biotechnology company’s stock worth $10,161,000 after buying an additional 188,679 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in shares of Rigel Pharmaceuticals by 7.8% during the first quarter. Jacobs Levy Equity Management Inc. now owns 217,776 shares of the biotechnology company’s stock worth $3,918,000 after buying an additional 15,687 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Rigel Pharmaceuticals in the first quarter valued at approximately $804,000. Institutional investors and hedge funds own 66.23% of the company’s stock.

About Rigel Pharmaceuticals

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.